Cost-Effectiveness of the Chimeric Antigen Receptor (CAR) T-Cell Treatments, Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel), as Second-Line (2L) Treatment of Large B-Cell Lymphoma (LBCL)-MedSci.cn

Cost-Effectiveness of the Chimeric Antigen Receptor (CAR) T-Cell Treatments, Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel), as Second-Line (2L) Treatment of Large B-Cell Lymphoma (LBCL)

Lunning, M; Deger, KA; Liu, FF; Elsada, A; Klijn, SL; Litkiewicz, M; Franco-Villalobos, C; Sorensen, SV

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023; 23 (): S517

科室
- - 订阅+
  - 更多科室
工具
服务